OptiNose develops specialty pharmaceutical products and Bi-Directional™ Exhalation Delivery Systems that use a patient’s exhaled breath to carry medicine high and deep into the nasal passages. Founded around the clinical experience of ENT surgeon Per Djupesland, the company has applied the platform to treatments including XHANCE® for nasal polyps and chronic sinusitis, while also licensing it for migraine therapy and exploring nose-to-brain delivery. OptiNose was acquired by Paratek Pharmaceuticals in May 2025.
California Annual Declaration of Compliance
Compliance program
Otomagnetics, IncOtomagnetics is developing a magnetic injection drug-delivery platform that uses a proprietary magnetic device and biodegradable particles to move therapies non-invasively into hard-to-reach ear and eye tissues. Founded by hearing and neuroscience researcher Didier Depireux, the Gaithersburg company has demonstrated delivery to inner- and middle-ear compartments in animal models, including middle-ear delivery without puncturing the eardrum. Its multidisciplinary team includes CEO Abhita Batra and Chief Medical Officer Karen Stierman, an otolaryngologist with an electrical-engineering background.GAITHERSBURG, MD
Monaghan Medical CorporationFrom its Plattsburgh, New York base, Monaghan Medical Corporation develops and manufactures respiratory-care devices, including the NasoNeb® powered nasal delivery system that brings clinic-inspired medication delivery into the home. The company’s mechanical-design work is supported by a Global Aerosol and Research Laboratory, and its broader respiratory portfolio includes AeroChamber®, Aerobika®, and AeroEclipse® brands.MEDINA, OH
Beyond Air, IncBeyond Air develops medical devices for inhaled nitric oxide therapy, with its LungFit systems generating nitric oxide on demand from room air for use from hospital to home. The company’s technology team includes inventors behind the first FDA-cleared nitric oxide delivery system, giving its current platform a direct link to the commercialization of inhaled nitric oxide therapy. Its work also emphasizes reducing the cylinders, chemicals, transport, and energy demands associated with conventional nitric oxide delivery.GARDEN CITY, NY
Transmucosis, LLCFounded by Dr. Herbert Heyneker and Dr. Xiaoping Zhu, Transmucosis develops protein-based nasal vaccines designed to activate both mucosal and systemic immunity. Its platform uses the human IgG Fc region and the FcRn receptor to transport vaccine molecules across respiratory epithelial barriers, with lead candidates focused on influenza and COVID-19. The company anticipates submitting investigational new drug applications for those candidates in the second half of 2026.CLARKSVILLE, MD